International Murex Technologies
This article was originally published in The Gray Sheet
Executive SummaryBegins overseas marketing of its Single Use Diagnostic System (SUDS) HIV-1/2 antibody test in Belgium, Denmark, Portugal, Singapore, South Africa, Spain, Thailand and the United Kingdom. Murex is marketing the test through distributors and a 200-plus person sales force. Murex says it does not plan to sell the HIV-1/2 test in the U.S. The firm's SUDS HIV-1 antibody test has been sold in the U.S. since June ("The Gray Sheet" June 1, p. 25).
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.